The first of a new generation of drugs to fight flu has won approval in
Australia and Sweden. Other countries are expected to follow suit.
Zanamivir, marketed by Glaxo Wellcome, blocks a viral enzyme called
neuraminidase, which allows the virus to escape from infected cells. It will be
inhaled to lessen flu symptoms, but researchers also hope that it will work as a
preventive measure.
